Treatment of Metastatic Carcinoid Tumors With Radiolabeled Biologic Molecules

de Jong M, Kwekkeboom D, Valkema R et al.. Radiolabeled peptides for tumour therapy: current status and future directions. Eur J Nucl Med Mol Imaging 2003;30:463–469.

de JongMKwekkeboomDValkemaR. Radiolabeled peptides for tumour therapy: current status and future directions. Eur J Nucl Med Mol Imaging 2003;30:463–469. )| false
• Search Google Scholar
• Export Citation

Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al.. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S–66S.

KwekkeboomDJMueller-BrandJPaganelliG. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S–66S. )| false
• Search Google Scholar
• Export Citation

Paganelli G, Zoboli S, Cremonesi M et al.. Receptor mediated radionuclide therapy with 90Y-DOTA-D-phe1-try3-octreotide: Preliminary report in Cancer patients. Cancer Biother Radiopharm 1999;14:477–483.

PaganelliGZoboliSCremonesiM. Receptor mediated radionuclide therapy with 90Y-DOTA-D-phe1-try3-octreotide: Preliminary report in Cancer patients. Cancer Biother Radiopharm 1999;14:477–483. )| false
• Search Google Scholar
• Export Citation

Bushnell D, O’Dorisio T, Menda T et al.. Evaluating the clinical effectiveness of 90Y-SMT-487 in patients with neuroendocrine tumors. J Nucl Med 2003;44:1556–1560.

BushnellDO’DorisioTMendaT. Evaluating the clinical effectiveness of ⁹⁰Y-SMT-487 in patients with neuroendocrine tumors. J Nucl Med 2003;44:1556–1560. )| false
• Search Google Scholar
• Export Citation

Waldherr C, Pless M, Maecke HR et al.. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 Gbq 90Y-DOTATOC. J Nucl Med 2002;43:610–616.

WaldherrCPlessMMaeckeHR. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 Gbq ⁹⁰Y-DOTATOC. J Nucl Med 2002;43:610–616. )| false
• Search Google Scholar
• Export Citation

Tuenissen JJM, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with 177Lu-DOTA-octreotate. J Clin Oncol 2004;22:2724–2729.

TuenissenJJMKwekkeboomDJKrenningEP. Quality of life in patients with gastroenteropancreatic tumors treated with ¹⁷⁷Lu-DOTA-octreotate. J Clin Oncol 2004;22:2724–2729. )| false
• Search Google Scholar
• Export Citation

Hörsch D, Prasad V, Baum RP. Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4517.

HörschDPrasadVBaumRP. Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4517. )| false
• Search Google Scholar
• Export Citation

Valkema R, Pauwels S, Kvols LK et al.. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3] Octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147–156.

ValkemaRPauwelsSKvolsLK. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3] Octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147–156. )| false
• Search Google Scholar
• Export Citation

McCarthy KE, Powers A, Lemen L et al.. Dosimetry of 111In-pentetreotide predicts response to high dose radiotherapy with somatostatin analogs in patients with gastropancreatic tumors. J Nucl Med 2002;43:34P.

McCarthyKEPowersALemenL. Dosimetry of ¹¹¹In-pentetreotide predicts response to high dose radiotherapy with somatostatin analogs in patients with gastropancreatic tumors. J Nucl Med 2002;43:34P. )| false
• Search Google Scholar
• Export Citation

de Jong M, Breeman WAP, Valkema R et al.. Combination radionuclide therapy using 177Lu and 90Y labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):13S–17S.

de JongMBreemanWAPValkemaR. Combination radionuclide therapy using ¹⁷⁷Lu and ⁹⁰Y labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):13S–17S. )| false
• Search Google Scholar
• Export Citation

Valkema R, Pauwels S, Kvols L et al.. Long term follow-up of renal function after peptide receptor radiation therapy with 90Y DOTA-try3-octreotide and 177Lu DOTA-try3-octreotate. J Nucl Med 2005;46:83–91.

ValkemaRPauwelsSKvolsL. Long term follow-up of renal function after peptide receptor radiation therapy with ⁹⁰Y DOTA-try3-octreotide and ¹⁷⁷Lu DOTA-try3-octreotate. J Nucl Med 2005;46:83–91. )| false
• Search Google Scholar
• Export Citation

de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43:617–625.

de JongMKrenningE. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43:617–625. )| false
• Search Google Scholar
• Export Citation

Jamar F, Barone R Mathieu I et al.. 86Y-DOTA-D-Phe1-Try3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510–518.

JamarFBarone R MathieuI. ⁸⁶Y-DOTA-D-Phe¹-Try³-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510–518. )| false
• Search Google Scholar
• Export Citation

Bushnell D, Menda Y, O’Dorisio T et al.. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487 [OctreoTher™]) treatment. Cancer Biother Radiopharm 2004;19;35–45.

BushnellDMendaYO’DorisioT. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487 [OctreoTher™]) treatment. Cancer Biother Radiopharm 2004;19;35–45. )| false
• Search Google Scholar
• Export Citation

Rolleman EJ, Valkema R, de Jong M et al.. Safe and effective inhibition of renal uptake of radiolabeled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9–15.

RollemanEJValkemaRde JongM. Safe and effective inhibition of renal uptake of radiolabeled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9–15. )| false
• Search Google Scholar
• Export Citation

Barone R, Boroson-Chazot F, Valkema R et al.. Patient specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46(Suppl 1):99–106.

BaroneRBoroson-ChazotFValkemaR. Patient specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46(Suppl 1):99–106. )| false
• Search Google Scholar
• Export Citation

Bomanji JB, Wong W, Gaze MN et al.. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol) 2003;15:193–198.

BomanjiJBWongWGazeMN. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol) 2003;15:193–198. )| false
• Search Google Scholar
• Export Citation

Safford SD, Coleman RE, Gockerman JP et al.. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004;101:1987–1993.

SaffordSDColemanREGockermanJP. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004;101:1987–1993. )| false
• Search Google Scholar
• Export Citation

Madsen M, Bushnell D, Juweid M et al.. Potential increased tumor-dose delivery with combined 131I and 90Y DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med 2006;47;660–667.

MadsenMBushnellDJuweidM. Potential increased tumor-dose delivery with combined ¹³¹I and ⁹⁰Y DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med 2006;47;660–667. )| false
• Search Google Scholar
• Export Citation

Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996;32A:1924–1932.

TaalBGHoefnagelCAValdes OlmosRABootH. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996;32A:1924–1932. )| false
• Search Google Scholar
• Export Citation

Kaltsas G, Korbonits M, Heintz E et al.. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895–902.

KaltsasGKorbonitsMHeintzE. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895–902. )| false
• Search Google Scholar
• Export Citation

Quigley AM, Buscombe JR, Shah T et al.. Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study. Neuroendocrinology 2005;82:215–220.

QuigleyAMBuscombeJRShahT. Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study. Neuroendocrinology 2005;82:215–220. )| false
• Search Google Scholar
• Export Citation

Quigley AM, Buscombo JR, Gopinath G et al.. In-vivo characterisation of the functional aspects of carcinoid tumors by imaging somatostatin receptors and amine uptake [abstract]. J Nucl Med 2003;44:Abstract 74P.

QuigleyAMBuscomboJRGopinathG. In-vivo characterisation of the functional aspects of carcinoid tumors by imaging somatostatin receptors and amine uptake [abstract]. J Nucl Med 2003;44:Abstract 74P. )| false
• Search Google Scholar
• Export Citation

O’Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902–1909.

O’DonoghueJABardiesMWheldonTE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36:1902–1909. )| false
• Search Google Scholar
• Export Citation

Gaze MN, Mairs RJ, Boyack SM et al.. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 1992;66:1048–1052.

GazeMNMairsRJBoyackSM. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 1992;66:1048–1052. )| false
• Search Google Scholar
• Export Citation

de Jong M, Breeman WA, Bernard BF et al.. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841–1846.

de JongMBreemanWABernardBF. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841–1846. )| false
• Search Google Scholar
• Export Citation

de Jong M, Breeman WA, Valkema R et al.. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):13S–17S.

de JongMBreemanWAValkemaR. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):13S–17S. )| false
• Search Google Scholar
• Export Citation